Tenoxicam, a non-steroid anti-inflammatory of the oxicam type, has a m
olecular structure similar to that of piroxicam, but is more active an
d better tolerated. Several studies demonstrated that tenoxicam is a p
otent analgesic. It is completely absorbed after oral and intramuscola
r administration and slowly eliminated, the long half-life in tissues
consenting once-daily administration. In the present study the pharmac
okinetics of tenoxicam have been investigated during repeated parenter
al administration, with or without loading dose, in order to establish
the dose regime that produces constant tissue concentrations over tim
e. Thirty-six patients of both sexes, suffering from acute pain due to
arthritis of the spine, were enrolled in the study and divided into t
hree equal groups. The first group was given 40 mg tenoxicam per day (
single i.m. injection) for 2 days followed by 20 mg (single i.m. injec
tion) for 10 days. The second group received 20 mg i.m. once a day for
12 days. The third group received 20 mg i.m. twice a day for two days
followed by single 20 mg i.m. injections on the following days. Blood
was sampled at 0, 0.5, 1,2,4,6,8,12,16 and 24 hours and at 3,5,7,9 an
d 12 days. Tenoxicam levels in the samples were assayed by an HPLC met
hod. The results showed that single 40 mg loading doses for 2 days, fo
llowed by once-daily 20 mg maintenance administration, established the
requisite steady-state tissue concentrations of tenoxicam after the s
econd administration. Tenoxicam was very well tolerated in all three g
roups.